Encouraging follow-up data for BioNTech's CAR-T candidate BNT211

German biotech company BioNTech (Nasdaq: BNTX), which is aiming to diversify having raking in massive profits from its COVID-19 Comirnaty vaccine collaboration with US pharma giant Pfizer (NYSE: PFE), on Friday released positive clinical results with its novel CAR-T cell therapy candidate, BNT211, at the European Society for Medical Oncology (ESMO) Congress 2022.

The company presented positive follow-up data from its ongoing first-in-human Phase I/II trial evaluating the safety and efficacy of BNT211, in patients with relapsed or refractory advanced solid tumors. The results demonstrated encouraging signs of anti-tumor activity and the safety profile remained manageable for the two tested dose levels. BioNTech shares closed up 2.5% at $150.91 on Friday.

BNT211 is a novel therapeutic approach which comprises a synergistic combination of two of BioNTech’s proprietary platforms. The candidate combines an autologous chimeric antigen receptor (CAR) T cell therapy targeting the oncofetal antigen Claudin-6 (CLDN6) with a CLDN6-encoding CAR-T cell amplifying RNA vaccine (CARVac).